MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. HQY
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

HealthEquity (HQY) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

HealthEquity
NasdaqGS•Healthcare•Health Information Services
$93.36-2.71(-0.03%)Pre-market
Market Cap
$7.88B
P/E
33.3x
P/S
5.8x
P/B
4.0x

HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. It offers health savings accounts (HAS); investment platform; online-only automated investment advisory services through Advisor, a Web-based tool. The company also provides flexible spending accounts (FSA) for health and dependent care; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. In addition, the company offers HSA and FSA members with access to certain healthcare products, programs, and services through its marketplace. It serves clients through a direct sales force; and brokers and advisors, a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.

A

How this company scores

ExcellentMetricSide Score: 85/100

Strongest: Cash & Earnings Quality (25/25); weakest: Balance Sheet & Red Flags (19/25).

Profitability20/25
Growth21/25
Balance Sheet & Red Flags19/25
Cash & Earnings Quality25/25
Strengths
Rising free cash flowStrong marginsRising earningsLow leverage

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 33.3x5y range 29.8x – 517.1x
P/E 33.3x · below its 13-quarter median

Currently below its 13-quarter median.

P/S · 5.8x5y range 5.1x – 8.7x
P/S 5.8x · near its 20-quarter median

Currently near its 20-quarter median.

P/B · 4.0x5y range 3.1x – 4.5x
Price & Volume
Market Cap $7.88B

Metrics at a Glance

as of July 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$1.36B
7Q
Q. Revenue
$350.73M
8%
TTM EBITDA
$509.04M
7Q
TTM Op. Income
$351.41M
7Q
Q. Op. Income
$98.69M
10%
TTM Net Income
$236.49M
7Q
Q. Net Income
$65.64M
10%
EPS
$0.79
14%
Shares Out.
$83.37M
7Q
$1.36B in TTM revenue grew 7.3% YoY, reaching $350.73M last quarter. TTM EBITDA of $509.04M and TTM operating income of $351.41M show growth is flowing through to the bottom line. TTM net income of $236.49M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
73.5%
2Q
EBITDA Margin
40.1%
2Q
Op. Margin
28.1%
2%
Net Margin
18.7%
2%
Op. margin of 28.1% is up 0.6% YoY — cost efficiency is improving. Net margin at 18.7% and gross margin of 73.5% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 2% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
33.3x
43%
P/S Ratio
5.8x
14%
P/B Ratio
4.0x
1%
At 33.3x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 5.8x and P/B of 4.0x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 43% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$3.27B
4Q
Cash
$256.00M
2Q
Long-Term Debt
$931.06M
5Q
Book Value
$1.99B
4Q
D/E Ratio
0.5
2Q
Debt/EBITDA
6.6
2Q
With $3.27B in assets and $931.06M in long-term debt, D/E is 0.5and book value is $1.99B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has risen for 2 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$136.16M
0%
TTM Free Cash Flow
$487.73M
5Q
FCF Margin
35.8%
24%
FCF / Net Income
2.1
7Q
TTM FCF of $487.73M on $136.16M in operating cash flow. The FCF / Net Income ratio of 2.1x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 5 consecutive quarters — an improving trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 4.0x
· near its 20-quarter median

Currently near its 20-quarter median.